The state adjusts the maximum retail price of some medicines. Heilongjiang promulgates a guide price list

From Dec. 12th, the country reduced the maximum retail price of ceftriaxone and other individually-priced drugs, covering antibiotics, cardiovascular and cerebrovascular diseases and other 17 categories of drugs. The adjusted price is reduced by an average of 19% from the current stipulated price, and is expected to reduce the burden on the people by nearly 2 billion yuan each year. The Heilongjiang Provincial Price Supervision Bureau added and formulated the maximum retail price list for 37 specifications of medicines in accordance with the "Drug Bad Rates Rules (Trial)" and related regulations.
The current adjustment of prices, some of the commonly used drug retail prices significantly reduced. For example, the price of captopril (12.5 mg×20 tablets) produced by Sino-US Shanghai Shiguibao Pharmaceutical Co., Ltd. dropped from 34 yuan to 22.1 yuan, a drop of 35%; the price of Ceftriaxone (1 g injection) produced by Roche was 93.8. The yuan fell to 65.7 yuan, a decrease of 30%.

Prior to 2005, the National Development and Reform Commission imposed a premium on prices of drugs for specific companies, ie they were priced separately. In recent years, with the advancement of science and technology and the continuous expansion of market size, the production and operation costs of enterprises have declined to varying degrees. To this end, the National Development and Reform Commission has decided to reduce the high prices of drugs in batches in stages to further reduce the burden on medical expenses of the people.

Recently, the Heilongjiang Provincial Price Supervision Administration issued a notice that, for the highest retail price not specified in the National Development and Reform Commission's notice, the Provincial Price Supervision Bureau has formulated 37 specifications of medicines in accordance with the “Drug Bad Rates Regulation (Trial)” and related regulations. The maximum retail price list. At the same time, the prescribed procurement of medicines for bidding, if the retail price of the winning bid medicine is lower than the government-specified retail guidance price, may not be adjusted upwards; if the retail price of the winning bid medicine is higher than the government-set retail guidance price, it will be executed at the retail guiding price.